Medical & scientific approach
The research behind AfterSlim
AfterSlim is a dietary supplement, not a prescription drug. That doesn't mean the standards are lower. Here's the research and methodology that informed every choice in the formula.
How we choose strains
Each probiotic strain in AfterSlim had to clear three criteria before going into the capsule:
- Mechanism clarity. Published research must explain how the strain interacts with the gut barrier, the mucus layer, or short-chain fatty acid production. We don't include strains based on marketing claims.
- Dose-response evidence. Human trials must establish a working dose. We then formulate at or above that dose, not below it.
- Survivability. The strain has to survive room-temperature shipping and stomach acid. We use enteric-coated, moisture-locked capsules to keep CFU counts intact at the point of absorption.
How we choose prebiotics
A probiotic without its fuel is a seed without soil. We pair every strain in AfterSlim with a prebiotic fiber that human studies show feeds it:
- Chicory root inulin for Akkermansia muciniphila support. Cani et al. (2017) showed inulin can roughly triple Akkermansia abundance over 8 weeks.
- Resistant starch as colonic fermentation fuel that converts to butyrate, supporting the gut barrier and helping with satiety between GLP-1 doses.
The GLP-1 context
GLP-1 medications (semaglutide, tirzepatide, liraglutide) work primarily by slowing gastric emptying and influencing appetite signaling. A side effect of slowed emptying is that food sits longer, and the microbiome shifts accordingly. Specifically, Akkermansia muciniphila, a keystone gut strain, tends to decline.
AfterSlim is formulated to compensate for that shift: replenishing the strains that decline, feeding them with the right prebiotics, and supporting the mucus layer that GLP-1-induced slowdown can thin.
AfterSlim is not a GLP-1 agonist, does not affect blood sugar through the GLP-1 pathway, and is not a substitute for prescribed medication. It is a companion protocol for the gut.
Key references
- Cani PD, de Vos WM. Next-generation beneficial microbes: the case of Akkermansia muciniphila. Frontiers in Microbiology, 2017.
- Depommier C, et al. Supplementation with Akkermansia muciniphila in overweight and obese human volunteers: a proof-of-concept exploratory study. Nature Medicine, 2019.
- Plovier H, et al. A purified membrane protein from Akkermansia muciniphila or the pasteurized bacterium improves metabolism in obese and diabetic mice. Nature Medicine, 2017.
- Hagi T, Belzer C. The interaction of Akkermansia muciniphila with host-derived substances. Applied Microbiology and Biotechnology, 2021.
- Cani PD, et al. Akkermansia muciniphila: paradigm for next-generation beneficial microorganisms. Nature Reviews Gastroenterology & Hepatology, 2022.
Third-party testing
Every batch of AfterSlim is tested by an independent ISO 17025-accredited laboratory for:
- Strain identity and CFU potency at time of release and at end-of-shelf-life
- Heavy metals (lead, arsenic, cadmium, mercury) below USP limits
- Microbial safety (no detectable pathogens)
- Pesticide and gluten contamination
Test reports ship with every order. They are also available on request at support@afterslim.com.
Building our advisory board
We are recruiting clinicians who work directly with GLP-1 patients (endocrinologists, gastroenterologists, obesity medicine specialists, registered dietitians) to advise on product development and patient education. If that's you, we'd like to talk.
Get in touchInformation on this page is provided for educational purposes and is not a substitute for medical advice. Always consult your healthcare provider before starting any supplement, especially if you are on prescription medication, pregnant, or nursing.